May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Vitreous proteome analysis: An approach to the etiology of Diabetic Macular edema
Author Affiliations & Notes
  • M. Ouchi
    Ophthalmology, Kyoto Prefectural Univ Med, Kyoto, Japan
  • M. Kamei
    Ophthalmology, Osaka Univ, Osaka, Japan
  • K. West
    Ophthalmic Research,
    Cole Eye Institute, Cleveland, OH
  • K. Koizumi
    Ophthalmology, Kyoto Prefectural Univ Med, Kyoto, Japan
  • T. Yasuhara
    Ophthalmology, Kyoto Prefectural Univ Med, Kyoto, Japan
  • M. Tei
    Ophthalmology, Kyoto Prefectural Univ Med, Kyoto, Japan
  • H. Komori
    Ophthalmology, Kyoto Prefectural Univ Med, Kyoto, Japan
  • T. Yamamoto
    Ophthalmology, Kyoto Prefectural Univ Med, Kyoto, Japan
  • J. Crabb
    3) Ophthalmic Research,
    Cole Eye Institute, Cleveland, OH
  • S. Kinoshita
    Ophthalmology, Kyoto Prefectural Univ Med, Kyoto, Japan
  • Footnotes
    Commercial Relationships  M. Ouchi, None; M. Kamei, None; K. West, None; K. Koizumi, None; T. Yasuhara, None; M. Tei, None; H. Komori, None; T. Yamamoto, None; J. Crabb, None; S. Kinoshita, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 3460. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Ouchi, M. Kamei, K. West, K. Koizumi, T. Yasuhara, M. Tei, H. Komori, T. Yamamoto, J. Crabb, S. Kinoshita; Vitreous proteome analysis: An approach to the etiology of Diabetic Macular edema . Invest. Ophthalmol. Vis. Sci. 2004;45(13):3460.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Even in patients without vitreomacular traction, vitreous surgery can improve diabetic macular edema (DME). The effective mechanism(s) may be attributable to the removal of chemical mediators that prevail in the posterior vitreous cortex. To date, investigations have primarily focused on single DME–related proteins such as interleukin–6 (IL–6) and vascular endothelial growth factor (VEGE). We attempted to identify and analyze en mass the vitreous proteins of DME–related proteins using 2–dimensional electrophoresis and mass–spectrometry (MS). Methods: In the course of vitrectomy, samples (100 ul) were collected from the pre–macular posterior vitreous body of 4 eyes from 4 patients with non–DME pre–proliferative diabetic retinopathy (PPDR) (group 1) and 16 eyes from 14 DME patients (group 2). The total protein content in all samples was adjusted before two–dimensional electrophoresis. Spots visualized by silver staining were extracted for protein identification using the LC–MS/MS method and analysis software (PDQuestTM) was used to assess differences between the 2 groups. Results: A total of 212spots was detected in both groups. Of these, 64 spots from group 1 and 72 spots from group 2 were subjected to MS analysis. We found that 21 spots from group 1 and 22 spots from group 2 contained 13 and 14 proteins, respectively. Of these, 6 proteins in 10 spots from group 1 manifested intensity that was greater than 2–fold that of proteins found in group 2 and 2 protein in 2 spots from group 2 manifested intensity that was greater than 2–fold that of proteins found in group 1. Among the high–intensity proteins of group 1, we identified pigment epithelium–derived factor (PEDF) and apolipoprotein A–4 (ApoA–4) prostaglandin D2 synthetase. Conclusions: Our findings show that specific proteins not present in serum exist in the vitreous body of DME and PPDR patients. Moreover, the 2 groups differed with respect to protein types and their intensity, we posit that these chemical mediators presence in the posteriol vitreous fluid may play a role in the induction and/or pathogenesis of DME.

Keywords: proteomics • diabetic retinopathy • vitreous 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×